ArticleDiscover oncology2026
Tumor suppressor gene chondroadherin opposes migration and proliferation in breast cancer and predicts a good survival.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Proteoglycans in Breast Cancer: Friends and Foes.Biomolecules · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
To enhance breast cancer (BC) management, there is an urgent need for molecular prognostic markers and therapeutic targets. This study investigates the role of chondroadherin (CHAD) in BC prognosis and its potential as a therapeutic target, focusing on its correlation with cancer severity and patient survival. CHAD expression at both mRNA and protein levels was analyzed in multiple datasets, and survival analysis was conducted. Comparisons were made between groups with different metastasis tendencies, and associations with clinical and pathological stages were examined. CHAD knockdown in T47D and ZR75-30 cell lines was performed to assess effects on proliferation and migration. Overexpression of CHAD in the MDA-MB-231 cell line reduced cell proliferation capability. GO/KEGG enrichment analysis identified CHAD's roles in molecular functions, cellular components, and biological processes. Western blotting evaluated CHAD's impact on the PI3K/Akt signaling pathway. Results indicated that CHAD expression is significantly lower in high malignancy BC groups and is associated with poorer survival outcomes. Increased CHAD levels correlate with lower metastasis propensity and are typically seen in lower-grade BC patients. CHAD knockdown increased proliferation and migration in T47D and ZR75-30 cells. Enrichment analyses highlighted pathways like "focal adhesion," "ECM receptor interaction," "regulation of actin cytoskeleton," and "PI3K/Akt pathway." Western blotting confirmed that CHAD inhibits PI3K and Akt phosphorylation. In summary, CHAD serves as a tumor suppressor gene and potential prognostic biomarker in breast cancer by inhibiting cell migration and proliferation through cell adhesion and PI3K/Akt pathway inhibition. Reduced CHAD expression correlates with worse prognosis, suggesting its potential as a therapeutic target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.